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Summary Interleukin 2 (IL-2) immunotherapy has met with limited success in the treatment of renal cell
carcinoma (RCC) and malignant melanoma (MM). However, non-responders still account for up to 80% of
those patients receiving IL-2. A high concentration ofsoluble IL-2 receptor (sIL-2R) is commonly found in the
blood of such patients. We investigated the possibility that high sIL-2R concentration pretreatment may
interfere with the bioavailability of IL-2. The mean concentration of sIL-2R in plasma from patients with
MM, RCC and head and neck cancer was 3378 U ml-', 8778 U ml-' and 764 U ml-' respectively, compared
with 1315 U ml-' in plasma from healthy volunteers. Inclusion of plasma from patients with RCC and MM
patient plasma in cytotoxic T-lymphocyte leukaemic (CTLL) cell/IL-2 assays inhibited the ability of CTLL
cells to respond to IL-2, and an inverse correlation was found between the concentration of sIL-2R and the
growth response of CTLL cell to IL-2 (r = - 0.86, P = 0.003). Plasma with soluble IL-2R concentrations
greater than 3000 U ml-' produced a reduction in cell growth of more than 50% when included in CTLL IL-2
assays. The addition of increasing concentrations of IL-2 to cultures containing suppressive plasma failed to
restore CTLL cell growth response to normal. Failure to saturate sIL-2R by exogenous IL-2 addition therefore
suggests that another factor, initially present at a concentration similar to the sIL-2R concentration, is
responsible for the observed effect. Determination of the suppressive effect of patient plasma as presented here
may allow more effective IL-2 dosing schedules.
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The various effects attributed to any cytokine are initiated
through the interaction of that cytokine with specific recep-
tors present on the surface of the target cells. The receptors
modulate cytokine effects by, for instance, imposing require-
ments of multiple receptor occupancy for cell activation, or
by transducing primary signals in a cascade of signals which
result in modulation or shedding of similar or different recep-
tors, thus affecting the outcome of multiple signalling events.
To date there have been numerous reports concerning the
detection of naturally occurring soluble, often ligand-binding,
components of receptor complexes. These soluble receptors
have been found in blood and urine, and their ubiquity
suggests that the occurrence of soluble forms of cytokine
receptors is a general phenomenon.
Most soluble receptors retain the ability to bind their
ligand with the same or lesser affinity than their membrane-
bound form. Thus, while the specific function of soluble
receptors still remains to be determined, a number of reasons
for their occurrence have been suggested:
1. Receptors are shed as a mechanism to render the cells
that shed them less sensitive to the activity of their
ligands.
2. Shed receptors complexed to their ligand may act as
transport proteins, prolonging the half-life of their bound
ligand by preventing proteolysis and acting as a reservoir
of active factors.
3. Soluble receptors may act as antagonists by competing
with surface receptors for binding to ligand.
The inhibitory activity of soluble cytokine receptors may
have potential beneficial therapeutic use, for example in
reducing severe acute-phase responses. Little consideration,
however, has been given to the activity of soluble receptors
generated in response to neoplastic disease, or cytokine
therapy, in which the presence of potentially neutralising
soluble receptors may influence dosing schedules and
ultimately response rates to exogenously supplied cytokine(s).
With this consideration in mind, relatively rapid measure-
ment of circulating cytokine concentrations (based on
immunoavailability rather than bioavailability) would require
careful interpretation if the data were to be used in patient
management.
The advent of the cytokine interleukin 2 (IL-2) into the
clinic as an immunomodulatory drug has met with some
limited success in the treatment of renal cell carcinoma
(RCC) (reviewed by Gore, 1993) and malignant melanoma
(MM) (reviewed by Sparano and Dutcher, 1993). However,
non-responders still account for 70-88% of patients receiv-
ing IL-2 as their sole immunotherapeutic drug (Parkinson,
1989). In common with other solid tumours and lymphomas,
RCC and MM are associated with raised levels of serum IL-2
receptor (Rovelli et al., 1988). The biological and prognostic
significance of raised IL-2 receptor remains obscure. In this
study we test the hypothesis that one reason for the failure to
respond to IL-2 therapy may be the potential of circulating
soluble IL-2 receptor (sIL-2R) in the blood of tumour
patients to inhibit the bioavailability of IL-2.
Materials and methods
Test sample
Blood from five healthy volunteers, 14 patients with renal cell
carcinoma, 18 with malignant melanoma and 13 with head
and neck cancer was collected by venepuncture into Vacu-
tainers (Becton Dickinson) with lithium heparin anticoag-
ulant for plasma preparation, and subsequent determination
of sIL-2R concentration. Of these, plasma from five patients
with renal cell carcinoma, three patients with malignant
melanoma and five healthy volunteers were investigated for
IL-2-neutralising potential. A single patient with renal cell
carcinoma included in this investigation was on IL-2 therapy
at the time of blood collection.
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Measurement ofsoluble IL-2 receptor
The sIL-2R concentration was estimated using the T-cell
diagnostics sandwich enzyme-linked immunosorbent assay
(ELISA) (Laboratory Impex) applicable to the determination
of concentrations in human serum or plasma. All samples
were diluted 1:10 in diluent supplied with the kit before
assay, and assayed as recommended by the manufacturer.
Standard concentrations ranged between 0 and 3200 U ml-'
and the detection limit was 50 U ml-' sIL-2R. The intra- and
inter-assay precision quoted for the assay was between 2.2
and 3.4 and between 4.8 and 5.6 respectively.
Maintenance ofthe CTLL cell line
The IL-2-dependent cytotoxic T-lymphocyte leukaemic (CT-
LL) murine cell line was maintained in RPMI-1640 con-
taining 5% fetal calf serum, 20 mM glutamine, 50ytg ml-'
gentamicin sulphate, 5 x 10-5M 2-mercaptoethanol and
50 U ml1' IL-2 (Eurocetus UK). CTLL cells were plated at
2.5 x 104ml1' in 25cm2 flasks, incubated at 37°C in 5%
carbon dioxide and subcultured into fresh medium every 3
days.
IL-2 bioassay
Assays were performed in flat-bottomed 96-well tissue culture
plates. CTLL cells, washed three times in RPMI-1640, were
plated at I05ml-' (100jld per well) in medium containing no
IL-2. A 50 LI volume of culture medium and 50 tl of IL-2 at
final concentrations between 0.2 and 250 U ml1 were
separately added to the wells. Each dose of IL-2 was assayed
in triplicate. Because it had previously been reported that
CTLL cells may also be maintained by mouse IL-4 (Daynes
et al., 1990), a comparable responsiveness of the cell line to
recombinant human IL-4 (NIBSC, UK) was investigated
using concentrations of IL-4 identical to those used for deter-
mining IL-2 responsiveness.
To test for the inhibitory action of plasma sIL-2R on IL-2
bioavailability for CTLL growth, plasma samples were first
diluted 1:6.25 in culture medium without IL-2 and subs-
tituted for the 50ytl ofculture medium used in preparation of
standard dose-response reactions. The final dilution of
plasma in any well was 1:25, which was sufficient to prevent
plasma non-specifically interfering with cell growth. Plates
were incubated for 36 h. The cells were pulsed with tritiated
thymidine (1.86 MBq 25 tl1'l per well) for the final 18 h, after
which time they were harvested onto filter paper discs and
the incorporation of radioactive nucleotide quantified by
liquid scintillation counting.
Statistical analysis
Comparison between groups was made using Mann-Whit-
ney two-tailed non-parametric statistics. Data points and
error bars on figures represent the mean ± 1 standard devia-
tion (s.d.). For data points with a s.d. <5%, the dimensions
of the point obscure the error bars. Correlation analysis was
by the method of Pearson.
Results
Plasma soluble IL-2R concentration
Soluble IL-2R was detectable in plasma samples from all
renal cell carcinoma and malignant melanoma patients, as
well as those from healthy volunteers; values are shown in
Table I. For plasma samples investigated for IL-2-
neutralising activity (Table II), the concentration of sIL-2R
varied greatly, with the mean concentration (excluding the
patient who had received IL-2) of 3378 U ml-' being
significantly raised (P<0.01) above the mean concentration
of 1315 Uml-' found in samples from healthy individuals. It
is noteworthy that our normal mean sIL-2R value exceeded
Table I Solubie IL-2R concentrations in the plasma of patients with
malignant melanoma (MM), renal cell carcinoma (RCC) and head and
neck (H&N) cancer before commencing IL-2 immunotherapy and in
healthy volunteers
MM RCC H&N Healthy
Number 18 14 13 5
Mean sIL-2R (U ml-') 3378 8778 764 1315
s.d. 1826 6988 428 861
Number with sIL-2R> 18 (100) 14 (100) 3 (23) 3 (60)
919Uml-' (%)
Number with sIL-2R> 7 (38) 10 (71) None None
3000 U ml-l(%)
Table II Plasma sIL-2R concentrations in patients with neoplastic
disease and healthy volunteers chosen for investigation of IL-2
neutralising ability
Sample Disease sIL-2R (Uml-')
1 Male MM 1221.0
2 Male RCC 1262.0
3 Female MM 2056.0
4 Male RCC 2995.0
5 Female MM 3343.0
6 Male RCC 5723.0
7 Male RCC 11 681.0
8 Malea RCC 30 504.0
9 Male Healthy 666.7
10 Male Healthy 692.7
11 Male Healthy 1099.4
12 Male Healthy 1352.0
13 Female Healthy 2767.5
RCC, renal cell carcinoma; MM, malignant melanoma. aPatient
receiving IL-2: 5.4 x 106 U in total.
the upper limit of normal sIL-2R concentration (919 U ml-';
mean + 2 s.d.), defined by the assay manufacturer using 50
healthy blood donors, and this may have resulted from the
small population size used in the present study.
Response ofCTLL cells to IL-2 and IL-4
Figure 1 shows three dose-response curves for IL-2 and one
for IL-4-stimulated CTLL cell growth. Maximal stimulation
of growth was observed at IL-2 concentrations greater than
31.25 U ml-'. In the presence of healthy human plasma con-
taining 1352 U ml' sIL-2R, the response of CTLL cells to
IL-2 was marginally, but not significantly, reduced compared
with cell growth in response to IL-2 alone. Maximum and
similar stimulation ofgrowth occurred at IL-2 concentrations
greater than 62.5 U ml-'. CTLL cells showed no respon-
siveness to recombinant human IL-4.
Inhibition ofIL-2-stimulated CTLL growth byplasmafrom
RCC and MMpatients
Inclusion of RCC or MM patient plasma in CTLL IL-2
assays inhibited the ability of CTLL cells to respond to IL-2.
Figure 1 shows the inhibitory effect of a representative
plasma from a patient with RCC, containing 2995 U ml-
sIL-2R, on the CTLL cell line response to IL-2. The
inhibitory effect of sIL-2-containing plasma was characterised
by a reduction in the magnitude of response to higher con-
centrations of IL-2 which were not returned to normal levels
(i.e. similar growth responses to IL-2 alone or IL-2 in the
presence of plasma from a healthy volunteer) by increasing
IL-2 concentrations.
Analysis of CTLL cell growth response to a fixed concen-
tration of IL-2 (125 ngml') in the presence of increasing
amounts of sIL-2R in patient plasma (Figure 2) revealed an
inverse correlation between the concentration of sIL-2R and
the growth of the cells in response to IL-2 (r = - 0.86;
P = 0.003) over the data range 2056-3343 U ml-' sIL-2R.slL-2R and IL-2 responsiveness
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Figure 1 CTLL cell growth measured by incorporation of
tritiated thymidine in response to IL-4 (*), IL-2 alone (@) and
IL-2 plus plasma containing 1352 U ml-' sIL-2R (sample 11) (0)
and 2995 U ml-' sIL-2R (sample 4) (O).
These data do not support the hypothesis that endogenously
induced sIL-2R is able to restrict the bioavailability of IL-2.
The significant correlation between sIL-2R concentration and
cellular response suggests, however, that another humoral
factor present in patient plasma paralleling the sIL-2R con-
centration is responsible for the observed effects.
Interestingly, plasma with a sIL-2R concentration of
30 504 U ml-' from a patient receiving IL-2 produced a 66%
reduction in the growth response of CTLL cells stimulated
with IL-2 compared with CTLL cells grown in the presence
of normal plasma. Although only a single observation, this
finding conforms with the previous data showing that total
inhibition of CTLL growth in response to IL-2 is never
achieved.
Discussion
Therapy with IL-2 achieves reproducible objective responses
in 20-30% of patients with malignant melanoma (MM) and
renal cell carcinoma (RCC) (Parkinson, 1989). The effic-
acious use of this cytokine in terms of activation of the
immune system and subsequent anti-cancer response is both
dose and schedule dependent (Gratma et al., 1993; Schneek-
loth et al., 1993). Variation in response, and indeed lack of
response, to IL-2 therapy, may be due in part to properties
of the tumour, as well as variation in the host response to
this cytokine. The data presented in this study show that
raised endogenous sIL-2R concentrations, generated as a
result of the tumour or induced by IL-2 therapy, correlate
with a lack of proliferative response to IL-2 in vitro. The
inverse correlation observed between the concentration of
sIL-2R present in the plasma of patients and the ability of
CTLL cells to respond to exogenously added IL-2 in the
presence of patient plasma could not, however, be attributed
to the sIL-2R as the addition of exogenous IL-2 to culture
did not overcome the inhibitory activity of the plasma.
Using methods similar to those described here, a study
reporting raised sIL-2R concentration in the serum of
patients with diffuse cutaneous leishmaniasis (DCL) and a
full IL-2 response by CTLL cells incubated with patient
serum suggested no association between serum concentra-
tions of sIL-2R and immunosuppression in vivo (Akuffo and
Maasho, 1994). However, while sera from DCL patients did
not reduce proliferation of the IL-2-dependent CTLL cell
Soluble IL-2R (U ml-')
Figure 2 Growth of CTLL cells in response to 125 ngml-' IL-2
in the presence of plasma samples containing increasing amounts
of endogenous sIL-2R. The response at 100% was determined in
the absence of plasma containing sIL-2R, and subsequent data
points generated using samples 10, 1, 3, 4, 5, 6, 7 and 8. One
hundred per cent growth represents 170000c.p.m.
line, sera from patients with visceral leishmaniasis did, with
the conclusion that serum factors other than sIL-2R were
responsible for blocking CTLL cell response to IL-2. While
the cancers described here and leishmaniasis are not com-
parable diseases, it is intriguing to speculate that similar,
non-sIL-2R-mediated, immunosuppressive responses may be
occurring.
Further circumstantial evidence that sIL-2 may not be
responsible for the immunosuppressive effects observed in
this instance may be obtained by considering the kinetics of
sIL-2R production. Although the bulk of i.v. bolus IL-2
administered to patients is cleared from the circulation within
30 min (Lotze et al., 1987), sIL-2R is induced at a much
slower rate, reaching peak serum concentrations up to 2
weeks after prolonged IL-2 administration (Lissoni et al.,
1991), and may take days to return to starting concentrations
on cessation of IL-2 (Lotze et al., 1985). Our assessment of
one patient on IL-2 therapy showed that, although the
plasma contained a very high concentration of sIL-2R
(30 504 U ml-'), suppression of growth of CTLL cells was
similar to that achieved by plasma containing sIL-2R concen-
trations as low as 3000-6000 U ml-'. Furthermore, inhibi-
tion of cell growth was never complete.
Our data suggest that the immunosuppressive agent(s) is
induced concomitantly with sIL-2R as a humoral factor. This
finding remains consistent with the observation that adoptive
cellular therapy, in which anti-cancer cells from the patient
are stimulated ex vivo with IL-2, washed and reinfused,
produces better remission rates than the disappointing results
achieved by infused IL-2 alone (Rosenberg, 1988).
Recently, a further T-cell stimulatory factor, originally
termed IL-T and now called IL-15, has been discovered.
Sharing some biological characteristics with IL-2, IL-15
stimulates T-cell proliferation via shared use of the IL-2p
receptor and induces lymphokine-activated killer cells. Both
of these activities are generally believed to be crucially impor-
tant for an effective anti-cancer response (Bamford et al.,
1994; Burton et al., 1994). While specific inhibitors of IL-2-
responsive cells have been reported (Krakauer, 1985), the
nature of the inhibitor present in patient plasma and its
possible interaction with IL-15 remain to be elucidated.
Likewise, the relationship between IL-2 and IL-15 during the
promotion of an effective anti-neoplasia response is still to be
determined. It is possible that inhibition of IL-15 activity
rather than IL-2 may be the more crucial activity in the
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If sIL-2R has no role in immunosuppression then what
role has it? Ironically, sIL-2R-mediated processes promoting
tumorigenicity exist; an immunomodulatory role has been
suggested for sIL-2R, in which it is postulated to prevent
lymphocytic infiltration into tumour tissue (Sharma et al.,
1991). Initially proposed to operate in breast carcinoma, this
particular activity remains to be demonstrated in other
cancers.
In conclusion, while IL-2 therapy may offer hope to some
patients with RCC, MM and other neoplastic disease,
optimum dosage regimens remain presently unresolved and
reliable predictors of clinical response have yet to be deter-
mined (Whittington and Faulds, 1993). The potential for
customising the therapy for individual cancer patients based
on their sIL-2R levels has been recognised; investigation of
sIL-2R levels before treatment in patients with Hodgkin's
lymphoma (Gause et al., 1991) and nasopharyngeal car-
cinoma (Lai et al., 1991) has indicated that low concentra-
tions of serum sIL-2R correlate with a good prognosis to
treatment while high concentrations do not. Although such
data may simply reflect cancer burden, determination of the
suppressive effect of patient plasma on the cellular response
to IL-2, as presented here, may well allow more effective IL-2
dosing schedules for individual patients throughout a course
of IL-2 treatment.
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